WAM
ATRA icon

Weiss Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Weiss Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-408
Closed -$144K – 324
2019
Q3 		$144K Buy
+408
New +$152K 0.01% 283

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Weiss Asset Management's ATRA Position: Q4 2019 in Review

Weiss Asset Management sold out of Atara Biotherapeutics (ATRA) in Q4 2019, closing a stake of 408 shares — an estimated $144K sold.

Weiss Asset Management first reported a position in ATRA in Q3 2019 and held it in 1 quarter. The position peaked at $144K in Q3 2019. 117 funds tracked by Wall St. Rank hold ATRA as of Q4 2019.

  • Weiss Asset Management reported no remaining Atara Biotherapeutics position as of Q4 2019 after selling out during the quarter.
  • Weiss Asset Management sold 408 Atara Biotherapeutics shares in Q4 2019, an estimated $144K.
  • Weiss Asset Management first reported a position in Atara Biotherapeutics in Q3 2019 and held it in 1 quarter.
  • Weiss Asset Management's Atara Biotherapeutics position peaked at $144K in Q3 2019.
  • 117 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2019.

Based on Weiss Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.